Here’s Who Just Picked Up Genvec Inc. (NASDAQ:GNVC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Genvec Inc. (NASDAQ:GNVC) reported that Mmcap International Inc. Spc has picked up 114,827 of common stock as of 2017-02-16.
The acquisition brings the aggregate amount owned by Mmcap International Inc. Spc to a total of 114,827 representing a 5.05% stake in the company.
For those not familiar with the company, GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
A glance at Genvec Inc. (NASDAQ:GNVC)’s key stats reveals a current market capitalization of 16.66 million based on 2.27 million shares outstanding and a price at last close of $7.15 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-16, Swirsky picked up 10,000 at a purchase price of $0.50. This brings their total holding to 252,500 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Genvec Inc. (NASDAQ:GNVC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Otonomy Inc. (NASDAQ:OTIC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Otonomy Inc. (NASDAQ:OTIC) reported that Federated Investors Inc /pa/. has picked up 2,937,800 of common stock as of 2017-02-14.
The acquisition brings the aggregate amount owned by Federated Investors Inc /pa/. to a total of 2,937,800 representing a 9.74% stake in the company.
For those not familiar with the company, Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
A glance at Otonomy Inc. (NASDAQ:OTIC)’s key stats reveals a current market capitalization of 460.46 million based on 30.19 million shares outstanding and a price at last close of $15.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-05-22, Capps picked up 1,600 at a purchase price of $24.35. This brings their total holding to 1,600 as of the date of the filing.
On the sell side, the most recent transaction saw Butt unload 1,456 shares at a sale price of $18.07. This brings their total holding to 9,458.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Otonomy Inc. (NASDAQ:OTIC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Broadfin Capital is Buying Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) reported that Broadfin Capital has picked up 8,200,000 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 8,200,000 representing a 9.88% stake in the company.
For those not familiar with the company, Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.
A glance at Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)’s key stats reveals a current market capitalization of 92.94 million based on 82.97 million shares outstanding and a price at last close of $1.13 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-12, O’keeffe picked up 20,000 at a purchase price of $0.81. This brings their total holding to 432,126 as of the date of the filing.
On the sell side, the most recent transaction saw Winship unload 22,800 shares at a sale price of $3.34. This brings their total holding to 74,131.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Goldman Sachs Group Inc. is Buying Retrophin Inc. (NASDAQ:RTRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Retrophin Inc. (NASDAQ:RTRX) reported that Goldman Sachs Group Inc. has picked up 696,852 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Goldman Sachs Group Inc. to a total of 696,852 representing a 1.8% stake in the company.
For those not familiar with the company, Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.
A glance at Retrophin Inc. (NASDAQ:RTRX)’s key stats reveals a current market capitalization of 821.45 million based on 37.73 million shares outstanding and a price at last close of $21.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Meckler picked up 5,000 at a purchase price of $15.31. This brings their total holding to 52,000 as of the date of the filing.
On the sell side, the most recent transaction saw Aselage unload 3,200 shares at a sale price of $21.30. This brings their total holding to 240,556.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Retrophin Inc. (NASDAQ:RTRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.
For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.
On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Salon Media Group, Inc. (OTCMKTS:SLNM) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Spear Point Capital Management Llc. has picked up 190,154,289 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Spear Point Capital Management Llc. to a total of 190,154,289 representing a 69.05% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized and Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Salon Media Group, Inc. (OTCMKTS:SLNM)’s key stats reveals a current market capitalization of 5.72 million based on 76.27 million shares outstanding and a price at last close of $0.100 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-04, Hambrecht picked up 10,261,429 at a purchase price of $0.35. This brings their total holding to 27,174,322 as of the date of the filing.
On the sell side, the most recent transaction saw Warnock unload 10,261,429 shares at a sale price of $0.35. This brings their total holding to 34,878,281.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Salon Media Group, Inc. (OTCMKTS:SLNM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Svlsf V, Llc. is Buying Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Svlsf V, Llc. has picked up 2,857,667 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,857,667 representing a 15.3% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)’s key stats reveals a current market capitalization of 23.71 million based on 18.65 million shares outstanding and a price at last close of $1.23 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-30, George picked up 12,422 at a purchase price of $12.00. This brings their total holding to 90,764 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Just Picked Up Ocular Therapeutix Inc. (NASDAQ:OCUL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocular Therapeutix Inc. (NASDAQ:OCUL) reported that Svlsf V, Llc. has picked up 1,605,207 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 1,605,207 representing a 6.5% stake in the company.
For those not familiar with the company, Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug.
A glance at Ocular Therapeutix Inc. (NASDAQ:OCUL)’s key stats reveals a current market capitalization of 198.42 million based on 28.76 million shares outstanding and a price at last close of $6.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-15, Sawhney picked up 45,300 at a purchase price of $7.85. This brings their total holding to 677,390 as of the date of the filing.
On the sell side, the most recent transaction saw Fortune unload 9,470 shares at a sale price of $17.16. This brings their total holding to 112,060.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocular Therapeutix Inc. (NASDAQ:OCUL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.